Patents by Inventor Otmar Schaaf

Otmar Schaaf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY MOLECULES FOR CANCER TREATMENT
    Publication number: 20240124581
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: September 1, 2023
    Publication date: April 18, 2024
    Inventors: Markus ZETTL, Ivo LORENZ, Otmar SCHAAF, Melanie WURM, Jean-Francois FORTIN, Scott Ronald BRODEUR, Keith A. CANADA, Lukasz CHLEWICKI, Walter Carroll DAVIDSON, Pankaj GUPTA, Priyanka GUPTA, Rocío K. PÉREZ, Joseph Robert WOSKA, Jr., Haiguang XIAO, Danlin YANG
  • Antibody molecules for cancer treatment
    Patent number: 11795219
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: October 24, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Walter Carroll Davidson, Pankaj Gupta, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Jr., Haiguang Xiao, Danlin Yang
  • Crystalline salts of a B-RAF kinase inhibitor
    Patent number: 11753409
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: September 12, 2023
    Assignee: Xynomic Pharmaceuticals, Inc.
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf
  • CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR
    Publication number: 20220204506
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: March 11, 2022
    Publication date: June 30, 2022
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf
  • Antagonizing CD73 antibody
    Patent number: 11312785
    Abstract: The present invention relates to novel antagonizing antibodies for CD73. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 13, 2019
    Date of Patent: April 26, 2022
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Irmgard Maria Rita Hofmann, Jennifer Ahlberg, Rajkumar Ganesan, Priyanka Gupta, Sven Mostboeck, Simon Plyte, Otmar Schaaf, Chia-Hung Tsai, Melanie Wurm, Markus Zettl, Jark Boettcher, Bruna De Andrade Pereira
  • Crystalline salts of a B-RAF kinase inhibitor
    Patent number: 11306086
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 19, 2022
    Assignee: Xynomic Pharmaceuticals, Inc.
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf
  • Antibody molecules for cancer treatment
    Patent number: 11028169
    Abstract: The present invention relates to novel anti-PD1 and anti-LAG3 antibody molecules. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: June 8, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Markus Zettl, Ivo Lorenz, Otmar Schaaf, Melanie Wurm, Jean-Francois Fortin, Scott Ronald Brodeur, Keith A. Canada, Lukasz Chlewicki, Priyanka Gupta, Rocío K. Pérez, Joseph Robert Woska, Haiguang Xiao, Danlin Yang
  • CRYSTALLINE SALTS OF A B-RAF KINASE INHIBITOR
    Publication number: 20200283433
    Abstract: The present invention is related to crystalline salts of N-(3-(5-((1-ethylpiperidin-4-yl)(methyl)amino)-3-(pyrimidin-5-yl)-1H-pyrrolo[3,2-b]pyridin-1-yl)-2,4-difluorophenyl)propane-1-sulfonamide, a RAF kinase Inhibitor, useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: October 26, 2018
    Publication date: September 10, 2020
    Inventors: Ulrike Werthmann, Gerd-Michael Maier, Bodo Betzemeier, Otmar Schaaf
  • Antagonizing CD73 Antibody
    Publication number: 20190352420
    Abstract: The present invention relates to novel antagonizing antibodies for CD73. The invention also relates to nucleic acids encoding such antibody molecules; to methods for preparing such antibody molecules; to host cells expressing or capable of expressing such antibody molecules; to compositions comprising such antibody molecules; and to uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
    Type: Application
    Filed: May 13, 2019
    Publication date: November 21, 2019
    Inventors: Irmgard Maria Rita HOFMANN, Jennifer AHLBERG, Rajkumar GANESAN, Priyanka Gupta, Sven MOSTBOECK, Simon PLYTE, Otmar SCHAAF, Chia-Hung TSAI, Melanie WURM, Markus ZETTL, Jark BOETTCHER, Bruna DE ANDRADE PEREIRA
  • Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
    Patent number: 8404674
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: March 26, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Heinz Stadtmueller, Guido Boehmelt, Harald Engelhardt, Ulrich Hirt, Otmar Schaaf, Irene Waizenegger
  • 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments
    Patent number: 8258129
    Abstract: The present invention encompasses compounds of general formula (1) wherein X and R1 to R3 are as defined in the disclosure, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Grant
    Filed: July 5, 2007
    Date of Patent: September 4, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Gerd Bader, Guido Boehmelt, Ralph Brueckner, Thomas Gerstberger, Maria Impagnatiello, Daniel Kuhn, Otmar Schaaf, Heinz Stadtmueller, Irene Waizenegger, Andreas Zoephel
  • Substituted indolines as tyrosine kinase inhibitors
    Patent number: 8207179
    Abstract: The present invention encompasses compounds of general Formula (1) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Grant
    Filed: June 9, 2008
    Date of Patent: June 26, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Harald Engelhardt, Bodo Betzemeier, Guido Boehmelt, Ulrich Guertler, Thomas Karner, Oliver Kraemer, Daniel Kuhn, Jens Juergen Quant, Ulrich Reiser, Otmar Schaaf, Flavio Solca, Heinz Stadtmueller, Ulrike Tontsch-Grunt, Matthias Treu, Stephan Karl Zahn
  • COMPOUNDS
    Publication number: 20100311721
    Abstract: The present invention encompasses compounds of general formula (1) wherein R1, R2 and R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: March 4, 2008
    Publication date: December 9, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Heinz Stadtmueller, Guido Boehmelt, Harald Engelhardt, Ulrich Hirt, Otmar Schaaf, Irene Waizenegger
  • NEW COMPOUNDS
    Publication number: 20100222331
    Abstract: The present invention encompasses compounds of general Formula (1) wherein R2, R3, Q, W, X, Y and Z are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.
    Type: Application
    Filed: June 9, 2008
    Publication date: September 2, 2010
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Harald Engelhardt, Bodo Betzemeier, Guido Boehmelt, Ulrich Guertler, Thomas Karner, Oliver Kraemer, Daniel Kuhn, Jens Juergen Quant, Ulrich Reiser, Otmar Schaaf, Flavio Solca, Heinz Stadtmueller, Ulrike Tontsch-Grunt, Matthias Treu, Stephan Karl Zahn
  • 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS
    Publication number: 20090203673
    Abstract: The present invention encompasses compounds of general Formula (I) wherein X and R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a pharmaceutical composition having the above-mentioned properties.
    Type: Application
    Filed: July 5, 2007
    Publication date: August 13, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Harald Engelhardt, Gerd Bader, Guido Boehmelt, Ralph Brueckner, Thomas Gerstberger, Maria Impagnatiello, Daniel Kuhn, Otmar Schaaf, Heinz Stadtmueller, Irene Waizenegger, Andreas Zoephel